Consistent with the results obtained with TILs, ImmTAC® molecules were capable of redirecting exhausted T cells against PD-L1− tumor cells; however, this redirection and killing were reduced up to five-fold against PD-L1+ tumor cells (Fig. S7b—left panel). This evidence concerns the gene CD274 and neoplasm.